JP2009507077A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507077A5 JP2009507077A5 JP2008530143A JP2008530143A JP2009507077A5 JP 2009507077 A5 JP2009507077 A5 JP 2009507077A5 JP 2008530143 A JP2008530143 A JP 2008530143A JP 2008530143 A JP2008530143 A JP 2008530143A JP 2009507077 A5 JP2009507077 A5 JP 2009507077A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- xaa
- acid sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 13
- ROHPMAMDFFHGCD-VIFPVBQESA-N 5-Hydroxytryptophan Chemical compound C1=CC(O)=C[C]2C(C[C@H](N)C(O)=O)=CN=C21 ROHPMAMDFFHGCD-VIFPVBQESA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 230000000087 stabilizing Effects 0.000 claims 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000016178 immune complex formation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Claims (12)
- 対象における免疫複合体形成を阻害するための医用薬剤の製造におけるポリペプチドの使用であって、該ポリペプチドがアミノ酸配列
を含み、Xaa1は任意のアミノ酸であり、Xaa2はArg、Trp、5-HTP、TyrまたはPheであり、Xaa3は任意のアミノ酸であり、かつnは0、1、2、3、4または5である、使用。
- ポリペプチドが末端安定化基（terminal-stabilizing group）を該ポリペプチドのアミノ末端に含み、該末端安定化基がアミノ酸配列Xaa-Pro-Proを有するトリペプチドであって、Xaaは任意のアミノ酸である、請求項1記載の使用。
- XaaがAlaである、請求項2記載の使用。
- ポリペプチドが約10〜約50アミノ酸の長さを有する、請求項1記載の使用。
- ポリペプチドがアミノ酸配列
を含む、請求項1記載の使用。 - ポリペプチドがアミノ酸配列
を含む、請求項1記載の使用。 - アミノ酸配列が
からなり、Xaa1は任意のアミノ酸であり、Xaa2はArg、Trp、5-HTP、TyrまたはPheであり、Xaa3は任意のアミノ酸であり、かつnは0、1、2、3、4または5である、精製されたポリペプチド。 - アミノ酸配列
を含む、請求項7記載の精製されたポリペプチド。 - アミノ酸配列
を含む、請求項7記載の精製されたポリペプチド。 - 精製されたポリペプチドを含む組成物であって、ポリペプチドがアミノ酸配列
を含み、Xaa1は任意のアミノ酸であり、Xaa2はArg、Trp、5-HTP、TyrまたはPheであり、Xaa3は任意のアミノ酸であり、かつnは0、1、2、3、4または5である組成物。 - ポリペプチドがアミノ酸配列
を含む、請求項10記載の組成物。 - ポリペプチドがアミノ酸配列
を含む、請求項10記載の組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71418005P | 2005-09-06 | 2005-09-06 | |
| US60/714,180 | 2005-09-06 | ||
| US77518406P | 2006-02-22 | 2006-02-22 | |
| US60/775,184 | 2006-02-22 | ||
| US77985306P | 2006-03-08 | 2006-03-08 | |
| US60/779,853 | 2006-03-08 | ||
| PCT/US2006/034603 WO2007030475A1 (en) | 2005-09-06 | 2006-09-06 | Methods for treating immune mediated neurological diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009507077A JP2009507077A (ja) | 2009-02-19 |
| JP2009507077A5 true JP2009507077A5 (ja) | 2009-10-22 |
| JP5329961B2 JP5329961B2 (ja) | 2013-10-30 |
Family
ID=37836151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530143A Expired - Fee Related JP5329961B2 (ja) | 2005-09-06 | 2006-09-06 | 免疫介在性神経疾患を治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20080187490A1 (ja) |
| EP (1) | EP1940436B1 (ja) |
| JP (1) | JP5329961B2 (ja) |
| CN (1) | CN101277714B (ja) |
| CA (1) | CA2621539C (ja) |
| WO (1) | WO2007030475A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005221187B2 (en) | 2004-03-10 | 2011-09-01 | Trinity Therapeutics, Inc. | Method for inhibiting immune complex formation in a subjetc |
| WO2009023777A2 (en) * | 2007-08-14 | 2009-02-19 | Trinity Therapeutics, Inc. | Methods for treating immune thrombocytopenia |
| CA2708492A1 (en) * | 2007-12-11 | 2009-06-18 | Genetech, Inc. | Modulators of neuronal regeneration |
| CN102159231B (zh) * | 2008-07-18 | 2016-06-15 | 三一治疗公司 | 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法 |
| CA2774999A1 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
| CN104324359B (zh) * | 2014-09-25 | 2016-08-17 | 中山大学 | Rry三肽在制备治疗阿尔茨海默症药物中的用途 |
| CN110684122B (zh) * | 2019-10-29 | 2021-03-02 | 中国人民解放军军事科学院军事医学研究院 | 重组Tau表位嵌合多聚体抗原、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189014A (en) * | 1979-12-03 | 1993-02-23 | Cowan Jr Fred M | Method of treating cellular Fc receptor mediated hypersensitivity immune disorders |
| US5693758A (en) * | 1987-11-19 | 1997-12-02 | 501 Research Corporation Limited | Immunoglobulin E competitor |
| US5932483A (en) * | 1990-10-16 | 1999-08-03 | Northwestern University | Synthetic peptide and its uses |
| AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US6420127B1 (en) * | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| JP2000505068A (ja) * | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| WO2001045746A2 (en) * | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20020164668A1 (en) * | 2000-04-03 | 2002-11-07 | Durham L. Kathryn | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease |
| WO2002038592A2 (de) * | 2000-11-08 | 2002-05-16 | Affina Immuntechnik Gmbh | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen |
| US6916904B2 (en) * | 2002-04-24 | 2005-07-12 | Zolaris Biosciences, Llc | Inhibition of immune complex formation |
| AU2005221187B2 (en) * | 2004-03-10 | 2011-09-01 | Trinity Therapeutics, Inc. | Method for inhibiting immune complex formation in a subjetc |
-
2006
- 2006-09-06 EP EP06802987.5A patent/EP1940436B1/en not_active Not-in-force
- 2006-09-06 US US11/470,566 patent/US20080187490A1/en not_active Abandoned
- 2006-09-06 JP JP2008530143A patent/JP5329961B2/ja not_active Expired - Fee Related
- 2006-09-06 CA CA2621539A patent/CA2621539C/en not_active Expired - Fee Related
- 2006-09-06 US US12/066,036 patent/US20090105138A1/en not_active Abandoned
- 2006-09-06 US US11/470,528 patent/US20080207498A1/en not_active Abandoned
- 2006-09-06 US US11/470,562 patent/US20080200392A1/en not_active Abandoned
- 2006-09-06 CN CN2006800366223A patent/CN101277714B/zh not_active Expired - Fee Related
- 2006-09-06 WO PCT/US2006/034603 patent/WO2007030475A1/en active Application Filing
-
2012
- 2012-01-12 US US13/348,773 patent/US20120115791A1/en not_active Abandoned
-
2016
- 2016-11-10 US US15/348,094 patent/US20170065670A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009507077A5 (ja) | ||
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| JP2019533722A5 (ja) | ||
| JP2011511753A5 (ja) | ||
| JP2013515057A5 (ja) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2005516885A5 (ja) | ||
| JP2013515055A5 (ja) | ||
| NZ599161A (en) | Method for activation of helper t cell and composition for use in the method | |
| JP2009268467A5 (ja) | ||
| JP2012518035A5 (ja) | ||
| JP2012176978A5 (ja) | ||
| TWI455721B (zh) | 癌疫苗組合物 | |
| JP2008514618A5 (ja) | ||
| JP2012500001A5 (ja) | ||
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| WO2008086086A3 (en) | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers | |
| JP2012115277A5 (ja) | ||
| JP2011518179A5 (ja) | ||
| JP2008517998A5 (ja) | ||
| JP2006158399A5 (ja) | 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤 | |
| JP2015509950A5 (ja) | ||
| JP2012529293A5 (ja) | ||
| JP2010265269A5 (ja) | ||
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy |